Drugs / Сarboplatine
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT05518383 Background | May 2022 → May 2025 overdue | Burkitt lymphoma, primary central nervous system lymphoma, primary mediastinal large B-cell lymphoma | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Сarboplatine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05518383 ↗ |